ETNB

$0.00

(

+0.00%

)
Quote details

stock

89bio Inc

NASDAQ | ETNB

14.84

USD

+$0.00

(

+0.00%

)

At Close (As of Oct 30, 2025)

$2.20B

Market Cap

-

P/E Ratio

-3.69

EPS

$15.06

52 Week High

$4.16

52 Week Low

HEALTHCARE

Sector

ETNB Chart

Recent Chart
Price Action

ETNB Technicals

Tags:

ETNB Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$38K
Total Revenue $0
Cost Of Revenue $38K
Costof Goods And Services Sold $38K
Operating Income -$385M
Selling General And Administrative $40M
Research And Development $345M
Operating Expenses $385M
Investment Income Net -
Net Interest Income $18M
Interest Income $24M
Interest Expense $3.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$13M
Income Before Tax -$366M
Income Tax Expense $692K
Interest And Debt Expense -
Net Income From Continuing Operations -$367M
Comprehensive Income Net Of Tax -
Ebit -$372M
Ebitda -$385M
Net Income -$367M

Revenue & Profitability

Earnings Performance

ETNB Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $479M
Total Current Assets $476M
Cash And Cash Equivalents At Carrying Value $126M
Cash And Short Term Investments $126M
Inventory -
Current Net Receivables -
Total Non Current Assets $2.2M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments $314M
Other Current Assets $36M
Other Non Current Assets -
Total Liabilities $78M
Total Current Liabilities $36M
Current Accounts Payable $15M
Deferred Revenue -
Current Debt -
Short Term Debt $727K
Total Non Current Liabilities $42M
Capital Lease Obligations $1.8M
Long Term Debt $36M
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $38M
Other Current Liabilities $20M
Other Non Current Liabilities $4.4M
Total Shareholder Equity $401M
Treasury Stock -
Retained Earnings -$825M
Common Stock $120K
Common Stock Shares Outstanding $105M

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$368M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization -$9.1M
Capital Expenditures $15K
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -$41M
Cashflow From Financing $219M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity $356K
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$367M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$38K
Total Revenue $0
Cost Of Revenue $38K
Costof Goods And Services Sold $38K
Operating Income -$385M
Selling General And Administrative $40M
Research And Development $345M
Operating Expenses $385M
Investment Income Net -
Net Interest Income $18M
Interest Income $24M
Interest Expense $3.8M
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization -$13M
Income Before Tax -$366M
Income Tax Expense $692K
Interest And Debt Expense -
Net Income From Continuing Operations -$367M
Comprehensive Income Net Of Tax -
Ebit -$372M
Ebitda -$385M
Net Income -$367M

ETNB News

ETNB Profile

89bio Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

89bio, Inc. (ETNB) is a clinical-stage biopharmaceutical company headquartered in San Francisco, California, specializing in the development of innovative therapies for liver and cardiometabolic diseases. The company focuses on addressing critical unmet medical needs through a promising pipeline of therapies that aim to enhance patient outcomes and overall quality of life. With a strong commitment to research and development, 89bio is strategically positioned to significantly contribute to advancements in the biopharmaceutical industry while creating sustainable shareholder value.

INTS
+394.56%
$1.32
VHAI
0.00%
$0.00
HBIO
+41.09%
$0.63
CMBM
+27.11%
$3.75
ASST
-3.20%
$1.21
NVDA
-2.00%
$202.89
PFE
0.00%
$24.29
BYND
-10.56%
$1.65
VIVK
-10.97%
$0.22
ABEV
+5.50%
$2.29
ONDS
-6.81%
$6.29
IXHL
+17.77%
$0.40
CMG
-18.18%
$32.53
YDKG
-11.47%
$0.04
AMZN
-3.23%
$222.86
MSAI
+30.69%
$1.32
NOK
-2.72%
$7.13
WTO
-10.72%
$0.04
META
-11.33%
$666.47
JZXN
+18.07%
$0.32
INTC
-2.85%
$40.15
T
-1.82%
$24.68
PLUG
-3.98%
$2.65
F
-1.35%
$13.06
TLRY
-5.14%
$1.29
DNN
+1.57%
$3.22
GOOGL
+2.51%
$281.48
BTG
+2.09%
$4.87
TSLA
-4.63%
$440.10
AAPL
+0.63%
$271.39
GPUS
-2.46%
$0.43
WULF
+2.20%
$14.82
BITF
-4.69%
$4.05
GLE
+32.35%
$0.86
SOFI
-6.05%
$29.03
AXDX
-61.36%
$0.03
RGTI
+7.89%
$42.52
FI
-7.66%
$65.19
BURU
-3.12%
$0.33
VCIG
+3.33%
$1.86
RIG
+2.08%
$3.91
CAN
-9.48%
$1.24
AAL
-1.46%
$12.78
ORIS
+17.11%
$0.16
ADAP
-15.14%
$0.05
CLF
-12.98%
$12.26
GOOG
+2.44%
$281.89
NLSP
+2.97%
$0.76
BBD
-3.69%
$3.39
VZ
-3.10%
$38.96
CORZ
-0.14%
$20.74
ETHD
+11.05%
$4.22
SNAP
-1.80%
$7.60
FMC
-46.52%
$15.53
TV
-2.54%
$2.68
AMD
-3.59%
$254.84
CERO
-94.68%
$0.09
QBTS
+5.39%
$36.11
MBRX
-5.79%
$0.45
PLTR
-2.14%
$194.55
LUMN
-6.00%
$10.34
BMY
+7.08%
$45.62
BMNR
-10.47%
$44.55
DVLT
-5.61%
$2.52
MSFT
-2.91%
$525.76
ACHR
-1.96%
$10.96
RIVN
-5.25%
$12.99
RMBL
+60.50%
$3.21
GRAB
-1.15%
$5.98
HPE
+0.57%
$24.41
ADTX
-40.61%
$0.06
CIFR
-2.65%
$19.07
VALE
+0.50%
$11.89
BTBT
-6.84%
$3.54
LAES
+9.19%
$6.89
ADD
-25.47%
$0.05
METU
-22.78%
$34.04
BAC
+0.85%
$53.03
KMX
-1.38%
$41.87
NIO
-1.82%
$7.01
PFSA
-9.85%
$0.25
AMCR
-1.87%
$7.85
WBD
+1.31%
$21.62
SRM
+53.27%
$10.30
KVUE
-0.48%
$14.24
MARA
-5.93%
$17.76
RXRX
-3.74%
$5.65
HBAN
+1.05%
$15.32
BENF
-10.29%
$0.55
AMC
-4.51%
$2.54
SOUN
-7.05%
$16.87
KHC
+0.82%
$24.58
RF
+0.54%
$24.20
AZTR
+18.52%
$0.59
AGNC
-0.59%
$10.00
WLGS
-5.57%
$0.04
ORCL
-6.68%
$256.89
RBLX
-15.50%
$113.00
EPWK
-1.78%
$0.06
IONZ
+2.80%
$3.67
INTS
+394.56%
$1.32
VHAI
0.00%
$0.00
HBIO
+41.09%
$0.63
CMBM
+27.11%
$3.75
ASST
-3.20%
$1.21
NVDA
-2.00%
$202.89
PFE
0.00%
$24.29
BYND
-10.56%
$1.65
VIVK
-10.97%
$0.22
ABEV
+5.50%
$2.29
ONDS
-6.81%
$6.29
IXHL
+17.77%
$0.40
CMG
-18.18%
$32.53
YDKG
-11.47%
$0.04
AMZN
-3.23%
$222.86
MSAI
+30.69%
$1.32
NOK
-2.72%
$7.13
WTO
-10.72%
$0.04
META
-11.33%
$666.47
JZXN
+18.07%
$0.32
INTC
-2.85%
$40.15
T
-1.82%
$24.68
PLUG
-3.98%
$2.65
F
-1.35%
$13.06
TLRY
-5.14%
$1.29
DNN
+1.57%
$3.22
GOOGL
+2.51%
$281.48
BTG
+2.09%
$4.87
TSLA
-4.63%
$440.10
AAPL
+0.63%
$271.39
GPUS
-2.46%
$0.43
WULF
+2.20%
$14.82
BITF
-4.69%
$4.05
GLE
+32.35%
$0.86
SOFI
-6.05%
$29.03
AXDX
-61.36%
$0.03
RGTI
+7.89%
$42.52
FI
-7.66%
$65.19
BURU
-3.12%
$0.33
VCIG
+3.33%
$1.86
RIG
+2.08%
$3.91
CAN
-9.48%
$1.24
AAL
-1.46%
$12.78
ORIS
+17.11%
$0.16
ADAP
-15.14%
$0.05
CLF
-12.98%
$12.26
GOOG
+2.44%
$281.89
NLSP
+2.97%
$0.76
BBD
-3.69%
$3.39
VZ
-3.10%
$38.96
CORZ
-0.14%
$20.74
ETHD
+11.05%
$4.22
SNAP
-1.80%
$7.60
FMC
-46.52%
$15.53
TV
-2.54%
$2.68
AMD
-3.59%
$254.84
CERO
-94.68%
$0.09
QBTS
+5.39%
$36.11
MBRX
-5.79%
$0.45
PLTR
-2.14%
$194.55
LUMN
-6.00%
$10.34
BMY
+7.08%
$45.62
BMNR
-10.47%
$44.55
DVLT
-5.61%
$2.52
MSFT
-2.91%
$525.76
ACHR
-1.96%
$10.96
RIVN
-5.25%
$12.99
RMBL
+60.50%
$3.21
GRAB
-1.15%
$5.98
HPE
+0.57%
$24.41
ADTX
-40.61%
$0.06
CIFR
-2.65%
$19.07
VALE
+0.50%
$11.89
BTBT
-6.84%
$3.54
LAES
+9.19%
$6.89
ADD
-25.47%
$0.05
METU
-22.78%
$34.04
BAC
+0.85%
$53.03
KMX
-1.38%
$41.87
NIO
-1.82%
$7.01
PFSA
-9.85%
$0.25
AMCR
-1.87%
$7.85
WBD
+1.31%
$21.62
SRM
+53.27%
$10.30
KVUE
-0.48%
$14.24
MARA
-5.93%
$17.76
RXRX
-3.74%
$5.65
HBAN
+1.05%
$15.32
BENF
-10.29%
$0.55
AMC
-4.51%
$2.54
SOUN
-7.05%
$16.87
KHC
+0.82%
$24.58
RF
+0.54%
$24.20
AZTR
+18.52%
$0.59
AGNC
-0.59%
$10.00
WLGS
-5.57%
$0.04
ORCL
-6.68%
$256.89
RBLX
-15.50%
$113.00
EPWK
-1.78%
$0.06
IONZ
+2.80%
$3.67

Charts powered by TradingView


Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.